NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers

Authors :: T.A. Yap
N. Ngoi
E.E. Dumbrava
D.D. Karp
J. Rodon Ahnert
S. Fu
D.S. Hong
A. Naing
S. Pant
S.A. Piha-Paul
V. Subbiah
A.M. Tsimberidou
D. Dufner
J. Rhudy
S. Gore
S.P. Ivy
Y. Yuan
S.N. Westin
G.B. Mills
F. Meric-Bernstam
Source :: European Journal of Cancer. 174:S7
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Full Text Access

Tools